BTN1A1, a component of the butyrophilin group , represents an intriguing therapeutic target for diverse immune disorders. The ICT-01-N297A immunoglobin , specifically designed to attach BTN1A1, offers a novel https://www.targetmol.com/compound/ict_01_n297a